PMH29 Cost Effectiveness of Quetiapine Extended Release Compared With Quetiapine Immediate Release in Schizophrenic Patients in Mexico  by Pozo Urquizo, L. et al.
to the WHO Commission on Macroeconomics and Health, RLAI is highly cost-
effective (1xGDP per-capita/QALY gained) in patients with a BARR between
63% and 72.5% and cost-effective (3xGDP per-capita /QALY gained) in patients
with a BARR between 35% and 63%. CONCLUSIONS: In all published naturalistic
studies comparing RLAI with oral medication, where the selection of patients to
receive RLAI is left to the physicians, the BARR is greater than 0.71, which
suggest that using RLAI in Mexico with similar criteria of patient selection
would result in a cost-saving strategy.
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OBJECTIVES: Evaluate the effectiveness of quetiapine extended release (XR) versus
quetiapine immediate release (IR) in Mexican Schizophrenic patients from a gov-
ernmental perspective.METHODS: Effective measurements were taken from Meu-
lien=s, et al, 2010 meta-analysis and a systematic review done for this analysis.
Cost-effectiveness and a cost utility analysis were done. Effectiveness measure-
ments were: percentage of patients adherent to treatment, reporting adverse
events (AEs) and with relapse. Disease-specific utility values assigned to each of the
6 schizophrenia disease states, based in the possible combinations of adherence
levels (full, partial, or nonadherence) and the relapse results, have been estimated
by Furiak, 2009 using the Positive and Negative Syndrome Scale, and expert opin-
ion. Costs considered are direct medical care, drug, AEs and relapse treatment.
Analysis used a governmental perspective (Mexican Institute of Social Services
costs), (published May 2012). A Markov model was performed considering a one
year horizon with 3 month cycles simulating schizophrenic Mexican population
with the proposed treatment alternatives. Finally a univariated probabilistic sen-
sitivity analysis was done to validate consistency in the model. RESULTS: The use
of quetiapine XR resulted in more adherent patients with 0.17846 compared with
0.05630 for quetiapine IR; less AEs reported with 0.13716 compared with 0.05462
respectively. In the cost-utility analysis quetiapine XR had an average QALYs of
0.14620 compared to quetiapine IR QALYS of 0.1256. Quetiapine XR generated a cost
saving of USD 508.52 (conversion rate: USD13.14 MxPesos. Average 2012).
CONCLUSIONS: Based on the data from the review and meta-analysis, quetiapine
XR had a similar efficacy and tolerability profile than quetiapine IR but with better
results in effectiveness measures (adherence, adverse events and QALYs). It re-
duces direct treatment costs in Mexican public Institutions with a positive estimate
impact. Based on these, quetiapine XR is a dominant alternative, more effective
and with less costs tan quetiapine IR.
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OBJECTIVES: Schizophrenia is marked by a characteristic interference pattern of
various psychological areas such as perception, ego-function, affectivity and
psychomotricity. Thus, the objective of this economic analysis is the evaluation
of the cost saving potential through the use of Paliperidone Palmitate compared
to Risperidon Depot. METHODS: The pharmaeconomic evaluation was per-
formed using a cost-minimization analysis, in which the above mentioned ther-
apeutic alternatives with equal effectiveness and efficiency are compared based
on the net costs to determine the most cost-effective alternative. The equiva-
lence of the comparators was confirmed in the study of Pandina et al. (2011).
Clinical data derived from this 13-week, double-blind head-to-head study. The
time horizon is 2-years. RESULTS: From the perspective of the health insurance,
the average costs of the therapy algorithm of Paliperidone Palmitate amount to
€5,024.02 for the first year of treatment. A patient treated with Risperidone
Depot is causing costs of €4,750.63. If the patient is treated with Paliperidone
Palmitate as a first-line treatment in the following year, costs of €4,222.32 arise.
In case of a treatment with Risperidone Depot costs amount to €4,594.76 EUR. If
a patient is treated with Paliperidone Palmitate throughout the period under
observation, the discounted total costs for 2-years amount to €9,247.02. Treat-
ment with Risperidone Depot is causing costs of €9,345.40, resulting in a cost
advantage for Paliperidone Palmitate compared to Risperidone Depot of €98.37
for the period of two years. Observing the costs over a time horizon of five years,
a treatment with Paliperidone Palmitate is causing costs in the amount of
20,008.15 EUR. For the same period, a treatment with Risperidone Depot is caus-
ing costs of €20,851.47. CONCLUSIONS: In the treatment of schizophrenia, Pali-
peridone Palmitate is a cost-effective alternative therapy. Additionally, the sen-
sitivity analysis shows that the analysis is, with the exception of doctor
consultations, robust.
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OBJECTIVES: To evaluate the cost-effectiveness of genetic screening for Apolipo-
protein 4 (APOE 4) allele in combination with preventive donepezil treatment in
comparison to the standard of care for Amnestic Mild Cognitive Impairment (AMCI)
patients in Canada.METHODS:We performed a cost-effectiveness analysis using a
Markov model with a societal perspective and a time horizon of 30 years. For each
strategy, we calculated quality-adjusted life years (QALYs) using utilities from the
literature. Costs were also based on the literature, and when appropriate, Ontario
sources. One-way and probabilistic sensitivity analyses were performed. Expected
value of perfect information (EVPI) was conducted to explore the value of future
research. RESULTS: The base case results in our exploratory study suggest com-
bined genetic testing and preventive donepezil treatment resulted in a gain of 0.011
QALYs and an incremental cost of CAD $394 compared to standard of care. The
incremental cost-effectiveness ratio (ICER) for the base case was $35,161 per QALY.
The ICER was sensitive to the effectiveness of donepezil treatment in delaying
progression to AD, and the costs of AD and donepezil. EVPI analysis showed that
additional information on these parameters would be of value. CONCLUSIONS:
Using presently available clinical evidence, this exploratory study illustrates ge-
netic testing combined with preventive donepezil treatment for AMCI patients may
be economically attractive. Since our results were based on a secondary post-hoc
analysis, our study alone is insufficient to warrant recommending APOE genotyp-
ing in AMCI patients. Future research on the effectiveness of preventive donepezil
as a targeted therapy is recommended.
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OBJECTIVES: This evaluation aimed to assess the cost-effectiveness of paliperi-
done palmitate in different lines of therapy for schizophrenia patients compared to
the current patient pathway. METHODS: A Markov model was developed that ex-
amined the use of five different treatment sequences, each involving paliperidone
palmitate at different points in the sequence. Variations in treatment sequences
were assessed to examine their impact on the model’s findings, and were com-
pared with a comparator treatment sequence reflecting current practice. The
model simulated the three main schizophrenic health states of remission, minor
relapse and major relapse. Adherence with medication is also taken into consider-
ation due to its impact on resource use, quality of life and the probability of relapse.
The model adopted a timeline of five years and used a Spanish health care provider
perspective. Drug costs are assumed to be ex factory. RESULTS: The difference in
costs associated with introduction of paliperidone palmitate at different moments
of patient course ranges from an additional €260 when used as a fourth-line ther-
apy to a reduction of €2,217 (i.e. cost saving) when directly used as a second-line
therapy after a course of daily risperidone treatment. Cost savings arose due to
reduced rates of relapse. All five treatment sequences resulted in an increase in
QALYs, ranging from 0.043 QALYs for fourth-line therapy to 0.124 QALYs per pa-
tient for second-line treatment. Second-line treatment was dominant to all other
treatment sequences. Probabilistic sensitivity analysis suggests that the probabil-
ity of paliperidone palmitate being cost-effective as a second-line therapy is 96.8%
at both €30,000 and €45,000 thresholds. One year analysis gave similar results, with
palmitate paliperidone as second-line therapy also dominant to all other treatment
sequences. CONCLUSIONS: Paliperidone palmitate used as second line after a
course of daily risperidone treatment is the dominant alternative when compared
to the other scenarios.
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OBJECTIVES: Schizophrenia is affecting the young adults and amounts to ap-
proximately 80,000 people in Austria, suffering at least one time during their life
from a psychotic episode, which meet the DSM-IV criteria of schizophrenia.
Patients with schizophrenia are at high risk of relapse due to non-adherence of
oral antipsychotic medication. The purpose of this analysis was to estimate the
cost-effectiveness of switching to Paliperidone palmitate after first-line oral
Olanzapine or Risperidone versus an oral treatment algorithm. METHODS: We
developed a Cost-Utility-Model to simulate the consequences of two treatment
algorithms; one with Paliperidone palmitate after treatment failure or stop of
Olanzapine or Risperidone versus a second with oral medication (starting with
Risperidone, Olanzapine, Quetiapine, Haloperidol, Ziprasidone and last-line
Clozapine, followed by no-treatment) over a 5-years horizon. Markov-modeling
techniques were used to estimate incidence of relapse, hospitalization, treat-
ment switch and death. Monte-Carlo simulation accounted for uncertainty. The
model includes eleven health-states. Probabilities were derived from clinical
studies. Direct medical costs from published sources were used and expressed
in 2011 Euro from the payer’s perspective. QALYs and costs were discounted at
5% p.a. RESULTS: Over a 5-year timeframe, costs associated with the use of
Paliperidone palmitate amounts to 28,328.94€ and 3.62 QALYs. Costs associated
with the oral treatment-path are 26,338.23€ and 3.20 QALYs. The incremental-
costs amount to 1,990.71€ per patient and the incremental-cost per QALY gained
was 4,739.79€. The Markov-cohort description shows that 55% of patients who
receive Paliperidone palmitate are still on treatment after 5-years and 24% have
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